
Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

Michael Mina, MD, PhD, is the CMO and chief epidemiologist at Invivyd.

Michael Mina, MD, PhD, discusses testing VMS063 against measles B3 and D8 genotypes and how it could fit alongside vaccination.

Michael Mina, MD, PhD, on why babies, immunocompromised patients, and the unvaccinated have the greatest need for a measles antibody.

Michael Mina, MD, PhD, of Invivyd, on measles antibody VMS063, immune amnesia, and what RSV antibody uptake signals for payers.

Michael Mina, MD, PhD, of Invivyd explains how a few amino acid changes let VYD2311 move from IV to a single IM shot that could expand access.

Michael Mina, MD, PhD, explains LIBERTY trial findings on VYD2311 tolerability alone and given with an mRNA COVID-19 vaccine.

Michael Mina, MD, PhD, explains Invivyd's accelerated approval path for VYD2311 and how it could change the timing of COVID-19 protection.

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most.

October 8th 2026

October 7th 2026